Pancreatic Cancer Research

ResearcherInsermNo recent work listed

Mehdi Ouaïssi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0906-4428; OpenAlex author ID A5016731047. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 7 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: 1 paper

Papers 16

  1. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Co-author DOI 10.3390/cancers12030618↗
  2. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Co-author DOI 10.1158/0008-5472.can-15-2790↗
  3. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  4. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individua… Co-author DOI 10.15252/emmm.201606975↗
  5. Venous Resection in Pancreatic Ductal Adenocarcinoma: Impact of Surgical Experience on Early Postoperative Courses. Co-author DOI 10.21873/anticanres.11811↗
  6. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Co-author DOI 10.1172/jci87734↗
  7. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  8. Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ajpath.2014.11.029↗
  9. Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. Co-author DOI 10.1016/s1499-3872(15)60397-6↗
  10. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Co-author DOI 10.1038/cddis.2014.557↗
  11. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1421601112↗
  12. Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence. Co-author DOI 10.18632/oncoscience.172↗
  13. A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Co-author DOI 10.18632/oncotarget.2685↗
  14. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.3510↗
  15. Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. Co-author DOI 10.1371/journal.pone.0108520↗
  16. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. Co-author DOI 10.1155/2011/315939↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 12 shared papers, 2014–2018 · strength 0.52
  2. Nelson Dusetti · 9 shared papers, 2015–2017 · strength 0.38
  3. Olivıer Turrini · 8 shared papers, 2015–2017 · strength 0.38
  4. Céline Loncle · 9 shared papers, 2014–2017 · strength 0.36
  5. Véronique Secq · 8 shared papers, 2015–2018 · strength 0.35
  6. Odile Gayet · 7 shared papers, 2015–2017 · strength 0.29
  7. Sophie Vasseur · 6 shared papers, 2015–2018 · strength 0.27
  8. Jean‐Robert Delpéro · 5 shared papers, 2015–2017 · strength 0.26
  9. Flora Poizat · 6 shared papers, 2015–2017 · strength 0.25
  10. Marine Gilabert · 6 shared papers, 2015–2017 · strength 0.25
  11. Marc F. Giovannini · 5 shared papers, 2015–2017 · strength 0.21
  12. Pauline Duconseil · 5 shared papers, 2015–2017 · strength 0.20
  13. Julie Roques · 4 shared papers, 2015–2018 · strength 0.19
  14. Fabienne Guillaumond · 4 shared papers, 2015–2018 · strength 0.18
  15. Richard Tomasini · 4 shared papers, 2015–2018 · strength 0.18
  16. Jérémy Nigri · 4 shared papers, 2015–2018 · strength 0.18
  17. Jean‐Luc Raoul · 4 shared papers, 2015–2017 · strength 0.17
  18. Dominique Farge Bancel · 2 shared papers, 2015–2020 · strength 0.16
  19. Christian Bressy · 3 shared papers, 2015–2018 · strength 0.15
  20. Julie Leca · 3 shared papers, 2015–2018 · strength 0.15
  21. Benjamin Bian · 3 shared papers, 2016–2017 · strength 0.13
  22. Anthony Gonçalvès · 3 shared papers, 2015–2017 · strength 0.12
  23. Igor Sielezneff · 3 shared papers, 2011–2015 · strength 0.11
  24. Daniel Pietrasz · 2 shared papers, 2016–2018 · strength 0.11
  25. Jean‐Baptiste Bachet · 2 shared papers, 2016–2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.